146 related articles for article (PubMed ID: 1124321)
1. DNA breaks in P288 tumor cells in mice after treatment with daunorubicin and adriamycin.
Schwartz HS
Res Commun Chem Pathol Pharmacol; 1975 Jan; 10(1):51-64. PubMed ID: 1124321
[TBL] [Abstract][Full Text] [Related]
2. Some determinants of the therapeutic efficacy of actinomycin D (NSC-3053), adriamycin (NSC-123127), and daunorubicin (NSC-83142).
Schwartz HS
Cancer Chemother Rep; 1974; 58(1):55-62. PubMed ID: 4521481
[No Abstract] [Full Text] [Related]
3. Potentiation of actinomycin D or adriamycin antitumor activity with DNA.
Marks TA; Venditti JM
Cancer Res; 1976 Feb; 36(2 Pt 1):496-504. PubMed ID: 1260747
[TBL] [Abstract][Full Text] [Related]
4. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression.
Schwartz HS; Grindey GB
Cancer Res; 1973 Aug; 33(8):1837-44. PubMed ID: 4720795
[No Abstract] [Full Text] [Related]
5. Alkali-labile regions and strand breaks in DNA from cells treated with daunorubicin.
Schwartz HS
J Med; 1976; 7(1):33-46. PubMed ID: 1064678
[TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin.
Deprez-de Campeneere D; Baurain R; Trouet A
Cancer Treat Rep; 1979 May; 63(5):861-7. PubMed ID: 455327
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukemia L1210 cells: comparison with adriamycin and 4'-(9-acridinylamino)methanesulfon-m-anisidide.
Zwelling LA; Kerrigan D; Michaels S
Cancer Res; 1982 Jul; 42(7):2687-91. PubMed ID: 6896293
[TBL] [Abstract][Full Text] [Related]
9. Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.
Giuliani F; Casazza AM; Di Marco A; Savi G
Cancer Treat Rep; 1981; 65(3-4):267-76. PubMed ID: 6263470
[TBL] [Abstract][Full Text] [Related]
10. Clinical studies with daunorubicin-DNA and adriamycin-DNA complexes: a review.
Trouet A; Sokal G
Cancer Treat Rep; 1979 May; 63(5):895-8. PubMed ID: 287556
[TBL] [Abstract][Full Text] [Related]
11. A characterization of the immunosuppressive activity of adriamycin and daunomycin on humoral antibody production and tumor allograft rejection.
Vecchi A; Mantovani A; Tagliabue A; Spreafico F
Cancer Res; 1976 Apr; 36(4):1222-7. PubMed ID: 944093
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of the in vivo resistance to adriamycin and modulation by calcium channel blockers in mice.
Yin MB; Bankusli I; Rustum YM
Cancer Res; 1989 Sep; 49(17):4729-33. PubMed ID: 2758408
[TBL] [Abstract][Full Text] [Related]
13. Nucleolar protein B23 translocation after doxorubicin treatment in murine tumor cells.
Chan PK; Aldrich MB; Yung BY
Cancer Res; 1987 Jul; 47(14):3798-801. PubMed ID: 2439199
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia.
Meriwether WD; Bachur NR
Cancer Res; 1972 Jun; 32(6):1137-42. PubMed ID: 5030814
[No Abstract] [Full Text] [Related]
15. DNA damage by anthracycline drugs in human leukemia cells.
Schwartz HS; Kanter PM
Cancer Lett; 1981 Sep; 13(4):309-13. PubMed ID: 6946856
[TBL] [Abstract][Full Text] [Related]
16. Effects of N-trifluoroacetyladriamycin-14-valerate and related agents on DNA strand damage and thymidine incorporation in CCRF-CEM cells.
Kanter PM; Schwartz HS
Cancer Res; 1979 Feb; 39(2 Pt 1):448-51. PubMed ID: 761217
[TBL] [Abstract][Full Text] [Related]
17. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin.
Yokota S; Hara H; Luo Y; Seon BK
Cancer Res; 1990 Jan; 50(1):32-7. PubMed ID: 2293557
[TBL] [Abstract][Full Text] [Related]
18. Correlations between cytotoxicity, biochemical effects, drug levels, and therapeutic effectiveness of daunomycin and adriamycin on Sarcoma 180 ascites in mice.
Silvestrini R; Lenaz L; Di Fronzo G; Sanfilippo O
Cancer Res; 1973 Nov; 33(11):2954-8. PubMed ID: 4748447
[No Abstract] [Full Text] [Related]
19. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
20. Modulation by adriamycin, daunomycin, verapamil, and trifluoperazine of the biochemical processes linked to mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Satyamoorthy K; Perchellet JP
Cancer Res; 1989 Oct; 49(19):5364-70. PubMed ID: 2475247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
